Emcure Pharmaceuticals Ltd management interview: A Steady Q2 For Emcure Pharmaceuticals | Zuventus, Our Arm, Expected To Ramp Up, Says Company |
CNBC-TV18, 2026-11-04. Video: https://www.youtube.com/watch?v=Qj0e7ymTw6E
- Raised guidance: Emcure now expects growth of 20%, versus mid-teens earlier, and expects margin expansion at the upper end of its guidance: 100 basis points.
- Domestic growth: Domestic growth was 12% last quarter against Indian industry growth of close to 15%. Emcure itself grew in line with the industry excluding Zuventus, which has been slower but is showing sequential improvement; management expects to match industry growth over the next 2 quarters.
- Growth priorities: Management cited renewed growth in Orofer XT and Orofer FCM, upcoming launches, and international pipeline opportunities. It is particularly bullish on Treprostinil, the liposomal platform and biologics, with biosimilars expected to contribute materially in the next 18 months.
- Margin drivers: Higher input and freight costs, along with international business nearing 60% of the mix, have weighed on gross margins. FX tailwinds and increased domestic contribution are helping offset this, and management expects healthy EBITDA margins despite slightly reduced gross margins.
- Longer-term outlook: Management’s aspiration is to sustain 20% growth while improving margins, supported by visibility from its pipeline and order book over the next 12 to 18 months.